<?xml version="1.0" encoding="UTF-8"?>
<ref id="B68-biomolecules-10-01625">
 <label>68.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lomeli</surname>
    <given-names>B.K.</given-names>
   </name>
   <name>
    <surname>Galbraith</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Schettler</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Saviolakis</surname>
    <given-names>G.A.</given-names>
   </name>
   <name>
    <surname>El-Amin</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Osborn</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Ravel</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Hazleton</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Lozupone</surname>
    <given-names>C.A.</given-names>
   </name>
   <name>
    <surname>Evans</surname>
    <given-names>R.J.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota</article-title>
  <source>Antimicrob. Agents Chemother.</source>
  <year>2020</year>
  <volume>64</volume>
  <fpage>e01395-19</fpage>
  <pub-id pub-id-type="doi">10.1128/AAC.01395-19</pub-id>
  <?supplied-pmid 31685472?>
  <pub-id pub-id-type="pmid">31685472</pub-id>
 </element-citation>
</ref>
